<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144642">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01936285</url>
  </required_header>
  <id_info>
    <org_study_id>COL.ACS</org_study_id>
    <nct_id>NCT01936285</nct_id>
  </id_info>
  <brief_title>Colchicine in ST-elevation Myocardial Infarction</brief_title>
  <official_title>Study of Anti-inflammatory Treatment With Colchicine in the Acute Phase of ST-elevation Myocardial Infarction to Reduce Infarct Size</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G.Gennimatas General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G.Gennimatas General Hospital</source>
  <oversight_info>
    <authority>Greece: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  There is evidence that inflammatory processes may play detrimental role during the
           acute phase of myocardial infarction

        -  The hypothesis of this study is that colchicine, by its anti-inflammatory action, may
           lead to reduction in infarct size, when administered during the acute phase of
           myocardial infarction
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Infarct size on MRI</measure>
    <time_frame>5 days post-MI</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Myocardial damage marker levels</measure>
    <time_frame>Days 1-3 post-MI</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients taking placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine 2 mg loading dose; 0.5 mg bid for 5 days</intervention_name>
    <arm_group_label>Colchicine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The study will enroll patients 18 years old or older who present to the hospital within
        twelve (12) hours of the onset of chest pain and who had ST segment elevation &gt;1 mm in two
        contiguous limb leads or ST segment elevation &gt;2 mm in two consecutive precordial leads or
        new onset of left bundle branch block (LBBB) in a twelve lead electrocardiogram and for
        whom the decision was made to be taken to the cath lab to perform angioplasty of the
        coronary vessels.

        Excluded patients:

          -  &gt; 80 years old

          -  with active inflammatory diseases, infectious diseases or known malignancy

          -  under treatment with corticosteroids, anti-inflammatory agents or disease modifying
             agents

          -  with known hypersensitivity-allergy to colchicine

          -  under chronic treatment with colchicine

          -  with severe renal failure (eGFR &lt; 30 ml/min/1.73 m2)

          -  with hepatic failure (Child - Pugh class B or C)

          -  presenting with cardiac arrest

          -  presenting with ventricular fibrillation

          -  presenting with cardiogenic shock

          -  with stent thrombosis

          -  with angina within 48 hours before infarction

          -  with previous myocardial infarction

          -  with occlusion of the left main or left circumflex coronary artery or with evidence
             of coronary collaterals to the region at risk on initial coronary angiography (at the
             time of admission)

          -  with metallic implants (ferromagnetic material)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Athens General Hospital &quot;G. Gennimatas&quot;</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Spyridon Deftereos, MD</last_name>
      <phone>+302107768560</phone>
      <email>spdeftereos@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Spyridon Deftereos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christos Angelidis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Georgios Giannopoulos, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 5, 2013</lastchanged_date>
  <firstreceived_date>September 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>G.Gennimatas General Hospital</investigator_affiliation>
    <investigator_full_name>Spyridon Deftereos</investigator_full_name>
    <investigator_title>Director, Cardiac Catheterization Department</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
